



ATTORNEY'S DOCKET NO.: B00801.70187.US
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 0 7 2002

Applicant(s): Michael B. Brenner et al.
Serial No.: 09/654,328
Conf. No.: 5793
Filed: September 1, 2000
For: METHODS AND COMPOSITIONS FOR TREATMENT OF
INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING
AGENTS
Examiner: Maher M. Haddad
Art Unit: 1644

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231 on October 28, 2002.

Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

Sir:

Transmitted herewith are the following:

- ☒ Response to Office Action dated April 26, 2002
- ☒ Appendix A: Marked-up Specification and Claims
- ☒ Appendix B: In vivo Data
- ☒ Appendix C: Arthritis and Rheumatism Abstract Record
- ☒ Appendix D: International Preliminary Examination Report for corresponding PCT application
- ☒ Declaration for Patent Application executed by Xavier Valencia (inventor)
- ☒ Updated Application Data Sheet
- ☒ Check in amount of \$460.00
- ☒ Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

A check is enclosed for \$460.00 (three month extension of time, small entity). **Applicants assert herewith small entity status.** If a further fee is required, please charge it to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

Maria A. Trevisan, Reg. No. 48,207
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel: (617) 720-3500

Docket No.: B00801.70187.US
Date: October 28, 2002
x10/26/02



Ext of time 3 mo

ATTORNEY'S DOCKET NO.: B00801.70187.US
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED *II 11/B*


NOV 07 2002

TECH CENTER 1600/2900

Applicant(s): Michael B. Brenner et al.
Serial No.: 09/654,328
Conf. No.: 5793
Filed: September 1, 2000
For: METHODS AND COMPOSITIONS FOR TREATMENT OF
INFLAMMATORY DISEASE USING CADHERIN-11 MODULATING
AGENTS
Examiner: Maher M. Haddad
Art Unit: 1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231 on October 28, 2002.


Maria A. Trevisan, Reg. No. 48,207

Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

Sir:

This is in response to the Office Action mailed from the U.S. Patent and Trademark Office on April 26, 2002. A three month extension of time is respectfully requested and the appropriate fee is submitted herewith.

Entity Status

Applicants had previously paid large entity fees in this case. Applicants are a small entity and are claiming small entity status. The fee submitted herewith is a small entity fee.

11/05/2002 SMINASS1 00000002 09654328

01 FC:2253

460.00 OP

In the Specification

Please re-write particular paragraphs of the specification as shown below. A marked-up version of this paragraph is provided in Appendix A.

Please re-write the paragraph beginning on page 24, line 4 as follows:

B1
In general, cadherin-11 homologs and alleles typically will share at least 70% nucleotide identity with SEQ. ID. NO: 1; and in some instances, will share at least 75% nucleotide identity; and in still other instances, will share at least 80% nucleotide identity. Watson-Crick